SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH Patent applications |
Patent application number | Title | Published |
20160082137 | Clinical Multimodality-Tools for Pre-And Intraoperative Insulinoma Diagnostics - A chemical compound has the general formula: Ex4-linker-Sar( | 03-24-2016 |
20160058733 | CDC7 KINASE INHIBITORS AND USES THEREOF - The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): | 03-03-2016 |
20160052955 | METHYLTRANSFERASE INHIBITORS FOR TREATING CANCERS - Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure | 02-25-2016 |
20160000329 | WIDE FIELD RAMAN IMAGING APPARATUS AND ASSOCIATED METHODS - Apparatus and methods are presented herein that permit real-time, accurate detection of residual tumor in the operating room. The Raman-based wide-field imaging apparatus and methods described herein permit real-time imaging of tumor-targeted R-MR nanoparticles over a wide field. | 01-07-2016 |
20150342723 | Ocular Prosthesis with Display Device - An ocular prosthesis includes a display device visible at an anterior portion of the ocular prosthesis. The display device is configured to present a changeable image that represents a natural appearance and movement for a visible portion of an eyeball of a subject. A system includes, besides the ocular prosthesis, an implant marker configured to move with an orbital implant disposed in an eye socket of a subject. A method includes determining a change in orientation of an orbital implant in a subject and determining an update to a natural appearance for a visible portion of an eyeball for the subject based on the change in orientation of the orbital implant. The method also includes rendering an update to an image of the natural appearance for a display device disposed in an ocular prosthesis configured to be inserted in the subject anterior to the orbital implant. | 12-03-2015 |
20150273011 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist. | 10-01-2015 |
20150216971 | Methods for Treating GI Syndrome and Graft versus Host Disease - It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, CGvHD disease, inflammatory diseases and autoimmune diseases. | 08-06-2015 |
20150191449 | SYNTHESIS OF THIOHYDANTOINS - A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52. | 07-09-2015 |
20150110807 | HDC-SIGN BINDING PEPTIDES - Polypeptides that bind to DC-SIGN and/or its homologues and methods for using such peptides for the treatment of various disorders are described. DC-SIGN and its homologues are receptors that bind IgG antibodies or Fc fragments and mediate intravenous immunoglobulin (IVIG)-related reversal of inflammation associated with various immune disorders. | 04-23-2015 |
20150080314 | TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING - Ocular analgesics for topical administration are described. The topical ocular analgesic includes a neo-tryptophan-containing neurotensin analog. The topical ocular analgesic may alternatively include a buffered salt solution, a local anesthetic solution, a tissue penetrating agent, and/or an opiate. The neo-tryptophan-containing neurotensin analog may be present in a dose of about 0.0005 to about 1.2 mg. | 03-19-2015 |
20150037346 | Prediction of Responsiveness to Treatment with Immunomodulatory Therapeutics and Method of Monitoring Abscopal Effects During Such Treatment - Efficacy of a therapeutic to enhance antitumor immunity in a patient is predicted, where the therapeutic is one that targets an immunomodulatory leukocyte membrane protein (ILMP) to enhance immune activity. Peripheral blood sample from the patient is tested for levels of monocytes having specific cell surface markers (CD14 | 02-05-2015 |
20150030583 | Methods of Treating Serosal Cancer - The discovery of clonally pure populations of serosal cancer stem cells (CSCs) as well as methods of producing CSCs, culturing the CSCs and using them in screening assays, has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of the glycocalyx coat surrounding such cells, and includes combination therapies using particular chemotherapeutics in conjunction with glycocalyx inhibitors, as well as the same new chemotherapy treatments without targeting the glycocalyx, where the chemotherapeutic agent is any one of LBH-589 (Panobinostat), NVP-AUY922, LAQ824 (NVP-LAQ824, Dacinostat), colchicine, brefeldin A, diphenyleneiodonium chloride, any combination thereof or another agent identified herein. These treatment methods of the invention can also be used in combination with radiation treatment or other conventional cancer therapy. | 01-29-2015 |
20140350534 | RAMAN BASED ABLATION/RESECTION SYSTEMS AND METHODS - Described herein are methods, systems, and devices for automated laser ablation and/or tissue resection triggered by Raman spectroscopic information. These systems and methods provide for precise removal of cancerous or other diseased tissue with minimal damage to adjacent healthy tissue. | 11-27-2014 |
20140315929 | HSP90 COMBINATION THERAPY - This invention concerns a method for selecting an inhibitor of a cancer-implicated pathway or of a component of a cancer-implicated pathway for coadministration, with an inhibitor of HSP90, to a subject suffering from a cancer which comprises the following steps:
| 10-23-2014 |
20140294725 | USES OF LABELED HSP90 INHIBITORS - The invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor. The disclosure provides a method for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor which comprises the following steps: (a) contacting the tumor or a sample containing cells from the tumor with a detectably labeled HSP90 inhibitor which binds preferentially to a tumor-specific form of HSP90; (b) measuring the amount of labeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample; and (c) comparing the amount of labeled HSP90 inhibitor bound to the tumor or the tumor cells in the sample measured in step (b) to the amount of labeled-HSP90 inhibitor bound to a reference. | 10-02-2014 |
20140288119 | NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE 1 - This invention provides a compound having the structure: | 09-25-2014 |
20140271817 | NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF - The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein. | 09-18-2014 |
20140248210 | MULTIMODAL SILICA-BASED NANOPARTICLES - The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle. | 09-04-2014 |
20140242602 | USES OF LABELED HSP90 INHIBITORS - The disclosure provides evidence that the abundance of this particular “oncogenic HSP90” species, which is not dictated by HSP90 expression alone, predicts for sensitivity to HSP90 inhibition therapy, and thus is a biomarker for HSP90 therapy. The disclosure also provides evidence that identifying and measuring the abundance of this oncogenic HSP90 species in tumors predicts of response to HSP90 therapy. “Oncogenic HSP90” is defined herein as the HSP90 fraction that represents a cell stress specific form of chaperone complex, that is expanded and constitutively maintained in the tumor cell context, and that may execute functions necessary to maintain the malignant phenotype. Such roles are not only to regulate the folding of overexpressed (i.e. HER2), mutated (i.e. mB-Raf) or chimeric proteins (i.e. Bcr-Abl), but also to facilitate scaffolding and complex formation of molecules involved in aberrantly activated signaling complexes (i.e. STATS, BCL6). | 08-28-2014 |
20140161814 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof. | 06-12-2014 |
20140113286 | Epigenomic Markers of Cancer Metastasis - Methods and kits for assessing risk of metastasis in a cancer patient identified as having breast cancer, colon cancer or glioma use analysis of a classifier for CpG island methylator phenotype. | 04-24-2014 |
20140112932 | Methods for Treating GI Syndrome and Graft versus Host Disease - We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases. | 04-24-2014 |
20140088121 | HSP90 Inhibitors - The disclosure relates to Compounds of Formulae (IA) and (IB): | 03-27-2014 |
20140045867 | HSP90 Inhibitors - The disclosure relates to Compounds of Formula (1) : | 02-13-2014 |
20140037673 | POLYVALENT CONJUGATE VACCINE FOR CANCER - This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Le | 02-06-2014 |
20140037551 | ANTIBODIES TO HUMAN B7X FOR TREATMENT OF METASTATIC CANCER - Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis. | 02-06-2014 |
20140031368 | SELECTIVE HDAC INHIBITORS - This disclosure is related to compounds having the structure | 01-30-2014 |
20140024705 | MIGRASTATINS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 01-23-2014 |
20140011844 | MIGRASTATIN ANALOGS AND USES THEREOF - The present invention provides compounds having formula (I): | 01-09-2014 |
20130324520 | RXRG MODULATORS FOR THE TREATMENT OF CANCER - The present invention provides methods for treating cancer using modulators of retinoid X receptor gamma (RXRG). The ability of RXRG antagonists to disrupt the association of complexes comprising RXRG is demonstrated. | 12-05-2013 |
20130323774 | HOMOGENOUS AND FULLY GLYCOSYLATED HUMAN ERYTHROPOIETIN - The present invention provides homogenous, fully-glycosylated, full length erythropoietin and the methods of producing the same. | 12-05-2013 |
20130225821 | SYNTHESIS OF THIOHYDANTOINS - A novel synthesis of the anti-androgen, A52, which has been found to be useful in the treatment of prostate cancer, is provided. A52 as well as structurally related analogs may be prepared via the inventive route. This new synthetic scheme may be used to prepare kilogram scale quantities of pure A52. | 08-29-2013 |
20130183295 | THERAPY-ENHANCING GLUCAN - This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition. | 07-18-2013 |
20130158017 | METHODS FOR TREATING OR PREVENTING CANCER AND NEURODEGENERATIVE DISEASES - Provided are methods of treating or preventing a neurodegenerative disease comprising administering to a subject having a neurodegenerative disease an effective amount of a compound of Formula I: | 06-20-2013 |
20130095173 | MULTIVALENT GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF - Glycopeptide conjugates comprising GM2 and/or Gb5 carbohydrate determinants, and methods of making and using such conjugates are disclosed. The immunogenicity of select glycopeptide conjugates is demonstrated. | 04-18-2013 |
20130053391 | Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin - T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m | 02-28-2013 |
20130039848 | FLUORESCENT SILICA-BASED NANOPARTICLES - The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as polyethylene glycol) (PEG) The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo The nanoparticle may further be conjugated to a ligand capable of binding to a cellular component associated with the specific cell type, such as a tumor marker A therapeutic agent may be attached to the nanoparticle Radionuclides/radiometals or paramagnetic ions may be conjugated to the nanoparticle to permit the nanoparticle to be detectable by various imaging techniques. | 02-14-2013 |
20130035321 | COMPOUNDS FOR THE TREATMENT OF OCULAR CANCER - In one aspect, the instant invention provides novel compounds and pharmaceutical compositions useful for treating proliferative diseases such as cancer. In another aspect, the invention provides methods of using certain compounds in the treatment of proliferative diseases such as cancer. In particular, the instant invention provides methods of treating ocular cancer (e.g., retinoblastoma) using intraarterial infusion to administer inventive compounds locally to the eye of a subject with an ocular cancer. | 02-07-2013 |
20130035301 | CDC7 KINASE INHIBITORS AND USES THEREOF - The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B) or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin. | 02-07-2013 |
20130011421 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF - The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation. | 01-10-2013 |
20120294872 | Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung - A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations. | 11-22-2012 |
20120276046 | ANTI GANGLIOSIDE GD3 ANTIBODIES AND USES THEREOF - The present invention is related to complementarity determining region (CDR)-grafted humanized R24 antibodies that bind to the GD3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine R24 antibody, and the humanized antibodies are useful in treating cancer (e.g. melanoma). | 11-01-2012 |
20120263749 | POLYVALENT CONJUGATE VACCINE FOR CANCER - This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Le | 10-18-2012 |
20120230464 | MULTI-SOURCE RADIATION SYSTEM AND METHOD FOR INTERWOVEN RADIOTHERAPY AND IMAGING - An arc radiotherapy and imaging system is provided which includes a first radiation source and a second radiation source. The first radiation source is suitable for treating a region of a patient, and the second radiation source is suitable for imaging the region of the patient. A control is also provided for automatically adjusting system operation, according to a defined schedule, between treating the region of the patient using the first radiation source and imaging the region of the patient using the second radiation source, thereby facilitating both treating and imaging of the region of the patient. | 09-13-2012 |
20120219506 | Catenae: Serosal Cancer Stem Cells - The present invention relates to a clonally pure population of serosal cancer stem cells (CSCs) as well as methods of producing and culturing the CSCs and uses thereof. The CSCs form catenae (free floating chains of cells) which have a glycocalyx coat of hyaluronan and proteoglycans. This discovery has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of glycocalyx formation, including combination therapies using chemotherapeutics in conjunction with glycocalyx inhibitors. The invention also provides drug screening assays for identifying compounds effective against these CSCs as well as other serosal cancer cells. Methods to use catena gene signatures, protein and surface antigens are provided for monitoring patient samples for the presence of serosal cancer stem cells. | 08-30-2012 |
20120208806 | Hsp90 Inhibitors - The present application provides compounds useful in the inhibition of Hsp90, and hence in the treatment of disease. | 08-16-2012 |
20120148549 | METHOD TO ISOLATE, IDENTIFY, AND USE EMBRYONIC STEM CELLS DIRECTED TO FOREBRAIN INTERNEURON FATE - The present invention relates to methods of isolating a purified or enriched population of cortical or striatal immature interneuron progenitor cells and the isolated purified or enriched population of immature interneuron progenitor cells. Methods of treating a condition mediated by a loss or deficiency of interneuron function using the purified or enriched population of immature interneuron progenitor cells are also disclosed. | 06-14-2012 |
20120071523 | BENZOFURAN-4,5-DIONES AS SELECTIVE PEPTIDE DEFORMYLASE INHIBITORS - The instant invention provides novel benzofuran-4,5-diones and pharmaceutical compositions thereof useful for inhibiting PDF and for treating proliferative and infectious diseases. Compounds may be selective for eukaryotic (e.g., human) PDF or prokaryotic PDF. | 03-22-2012 |
20110312980 | Small-molecule Hsp90 Inhibitors - Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands. | 12-22-2011 |
20110312904 | COMPOUNDS, COMPOSITIONS AND METHODS FOR REDUCING TOXICITY AND TREATING OR PREVENTING DISEASES - The present invention provides compounds of Formula (I), compositions comprising an effective amount of a compound of Formula (I), optionally with chemotherapeutic drugs such as a tubulin-binding drug, and methods of their use for reducing the toxicity of cytotoxic agents, treating or preventing cancer or a neuropathic disorder, inducing a chemoprotective phase II enzyme, DNA, or protein synthesis, enhancing the immune system, treating inflammation, improving and enhancing general health or well-being, and methods for making compounds of Formula (I). | 12-22-2011 |
20110312522 | METHODS OF DETECTION OF CANCER USING PEPTIDE PROFILES - The disclosed methods address the identification and monitoring of cancer in a subject using serum peptide profiles. Such profiles allow the detection of the differential presence of certain serum peptide markers in comparison with controls. The profiles can be determined employing mass spectrometry. | 12-22-2011 |
20110311651 | CARDENOLIDES FOR THE TREATMENT OF OCULAR CANCER - The instant invention provides methods of using a class of compounds known as cardenolides in the treatment of proliferative diseases such as cancer. In particular, the instant invention provides methods of treating ocular cancer {e.g., retinoblastoma) using intraarterial infusion to administer cardenolides locally to the eye of a subject with an ocular cancer. | 12-22-2011 |
20110306605 | COUMARIN-BASED COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND CANCER - Compounds including those of the Formula I | 12-15-2011 |
20110300073 | 18F-LABELLED THREE-AND FOUR-CARBON ACIDS FOR PET IMAGING - Compositions containing three and four-carbon acids labeled with | 12-08-2011 |
20110281916 | MIGRASTATIN ANALOGS AND USES THEREOF - The present invention provides compounds having formula (I): | 11-17-2011 |
20110266181 | MICROSCOPE SLIDE HOLDER AND METHOD OF USE - The present invention is a microscope slide holder suitable for use with a centrifuge. The slide holder includes a base with a plurality of chambers, the chambers being formed to receive and retain microscope slides. The slide holder may also include a seal, configured to cover the plurality of chambers, and a lid, which is removable from the base. The slide holder may also include a cover, which is configured to cover selected portions of the microscope slide. The method of using the microscope slide holder is also disclosed. | 11-03-2011 |
20110263663 | SYNTHESIS OF EPOTHILONES, INTERMEDIATES THERETO, ANALOGUES AND USES THEREOF - The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods for the treatment of cancer and cancer which has developed a multidrug-resistant phenotype. | 10-27-2011 |
20110257034 | METHODS FOR IDENTIFYING GENES WHICH PREDICT DISEASE OUTCOME FOR PATIENTS WITH COLON CANCER - Closures for containers and methods for using same are provided. In a general embodiment/the present disclosure provides a closure having a top portion ( | 10-20-2011 |
20110229510 | GLYCOPEPTIDE CONSTRUCTS AND USES THEREOF - Glycopeptide conjugates, and methods of making and using such conjugates are disclosed. Certain glycopeptide conjugates comprise tumor associated carbohydrate antigens and peptide epitopes. Certain glycopeptide conjugates comprise cyclic peptide scaffolds that display carbohydrate antigens in a clustered fashion. The immunogenicity of select glycopeptide conjugates is demonstrated. | 09-22-2011 |
20110206757 | NOVEL GLYCOCONJUGATES, GLYCOAMINO ACIDS, INTERMEDIATES THERETO, AND USES THEREOF - The present invention provides novel n-alkenyl glycosides and glycoconjugates, n-alkyl glycoamino acids, and methods for the synthesis thereof. In another aspect, the present invention provides novel clustered glycopeptides and methods for the synthesis thereof. In still another aspect, the present invention provides methods for the treatment of cancer, preferably for the prevention of recurrence of cancer, and methods for inducing antibodies in a subject, comprising administering to a subject in need, an effective amount of any of the inventive glycoconjugates as disclosed herein. | 08-25-2011 |
20110195071 | THERAPY-ENHANCING GLUCAN - This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection. | 08-11-2011 |
20110124731 | Treatment Of Neurodegenerative Diseases And Cancer Of The Brain Using Histone Deacetylase Inhibitors - The present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the neurogenerative disease is an inherited neurodegenerative disease, such as those inherited neurodegenerative diseases which are polyglutamine expansion diseases. The individual can be a mammal such as a primate or human. | 05-26-2011 |
20110123488 | Method of Treatment for Cancers Associated with Elevated HER2 Levels - Novel methods of treating proliferative disorders characterized by elevated Her-2, and the patient is then administered an effective amount of an HSP90 inhibitor. | 05-26-2011 |
20110116694 | RAPID CONFOCAL MICROSCOPY TO SUPPORT SURGICAL PROCEDURES - One embodiment of techniques for confocal microscopy includes illuminating a spot on a surface of a biological sample. A first emission intensity from the spot is detected in a first range of optical properties; and a second emission intensity in a second range. A pixel that corresponds to the spot is colored using a linear combination of the first and second emission intensities. Sometimes, the pixel is colored to approximate a color produced by histology. In some embodiments, a surface of a sample is contacted with a solution of acridine orange. Then, a spot is illuminated with a laser beam of wavelength about 488 nanometers (nm). Fluorescence emission intensity is detected above about 500 nm. Sometimes, a certain illumination correction is applied. In some embodiments, a sample holder that compresses a sample is removable from a stage that is fixed with respect to a focal plane of the microscope. | 05-19-2011 |
20110111436 | METHODS FOR ASSESSING CANCER FOR INCREASED SENSITIVITY TO 10-PROPARGYL-10-DEAZAAMINOPTERIN - Sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaaminopterin is assessed and patients are selected for treatment of cancer with 10-propargyl-10-deazaaminopterin, by determining the amount of a selected polypeptide expressed by the cancer and comparing the amount with the amount of the selected polypeptide expressed by a reference cancer. The polypeptide includes a member of a folate pathway polypeptide within a cell and may include at least one of reduced folate carrier-1 enzyme (RFC-1), dihydrofolate reductase (DHFR), folylpoly-gamma-glutamate synthetase (FPGS), thymidylate synthase (TS), γ-glutamyl hydrolase (GGH), and glycinamide ribonucleotide formyltransferase (GARFT). | 05-12-2011 |
20110104054 | Small-Molecule HSP90 Inhibitors - Hsp90 inhibitors having are provided having the formula: | 05-05-2011 |
20110092569 | Administration of Exogenous mi/siRNA - Certain genes controlled by endogenous miRNA are actually upregulated upon the transfection of exogenous mi/siRNA. Based on this, methods of determining whether administration of mi/siRNA will have a deleterious effect by upregulating certain genes are provided. Comparison of sequences of exogenous mi/siRNA allows selection of exogenous miRNA to be administered to cell to enhance or limit this affect, and therefore to control unwanted disregulation, or to upregulate an endogenous miRNA-regulated gene of interest. | 04-21-2011 |
20110071097 | CEPHALOTAXUS ESTERS, METHODS OF SYNTHESIS, AND USES THEREOF - The present invention provides novel cephalotaxus esters, syntheses thereof, and intermediates thereto. The invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of using said compounds or compositions in the treatment of proliferative diseases (e.g., benign neoplasm, cancer, inflammatory disease, autoimmune disease, diabetic retinopathy) and infectious disease. The invention further provides methods of using said compounds or compositions in the treatment of multidrug resistant cancer. | 03-24-2011 |
20110053804 | Gene Signatures for the Prognosis of Cancer - The cytokine TGFβ, in the tumor microenvironment, primes cancer cells for metastasis to the lungs. TGFβ response status (TBRS) can be determined by comparing expression levels of a panel of genes from cancer cells to the expression levels of the same genes in epithelial cell lines before and after induction with TGFβ. A TGFβ gene response signature reveals a clinical association between TGFβ activity in primary estrogen receptor negative (ER−) tumors and risk of lung metastasis. Further, combining the gene signature of the present invention with the known lung metastasis signature (LMS) increases the predictive value of the LMS considerably. | 03-03-2011 |
20110003754 | Peptide-Conjugated Oligonucleotide Therapeutic and Method of Making and Using Same - Conjugates for the efficient delivery of sequence-specific antisense to cells of a selected type for the inhibition of a target protein have the general formula: | 01-06-2011 |
20100330043 | GPR125 AS A MARKER FOR STEM AND PROGENITOR CELLS AND METHODS USE THEREOF - The present invention relates to GPR1 25 as a marker of stem and progenitor cells, including multipotent adult spermatogonial-derived stem cells (MASCs), spermatogonial stem and progenitor cells, skin stem or progenitor cells, intestinal stem or progenitor cells, neural stem or progenitor cells, and cancer stem cells. The invention provides, inter alia, methods for enriching or isolating GPR125-positive stem or progenitor cells, methods for detecting GPR125-positive stem or progenitor cells, methods for culturing GPR125-positive stem or progenitor cells, purified GPR125-positive stem or progenitor cells, therapeutic compositions containing purified GPR125-positive stem or progenitor cells, methods for targeting therapeutic agents to GPR125-positive stem and progenitor cells, and methods of treatment comprising administering GPR125-positive stem and progenitor cells, or differentiated cells derived therefrom, to subjects in need thereof. The present invention also provides methods of detecting cancer cells based on GPR1 25 expression, and methods of targeting therapeutic agents to cancer cells to GPR125-positive cancer cells. | 12-30-2010 |
20100310571 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof. | 12-09-2010 |
20100284920 | USES OF MONOCLONAL ANTIBODY 8H9 - This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides different uses of the monoclonal antibody 8H9 or its derivative. | 11-11-2010 |
20100273867 | THERAPY-ENHANCING GLUCAN - A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal, and at least one antibody for the cancer. A method of treating cancer in a mammal is also disclosed. The method comprises administering a suitable orally administered glucan and at least one antibody for the treatment of cancer to the mammal. In addition a composition for delivery of peptide, protein, RNA, DNA or plasmid comprising effective amount of a beta-glucan is disclosed. | 10-28-2010 |
20100239572 | METHODS FOR TREATING AND PREVENTING GI SYNDROME AND GRAFT VERSUS HOST DISEASE - We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases. | 09-23-2010 |
20100226914 | METHOD FOR PREPARATION OF SINGLE CHAIN ANTIBODIES - This invention provides a method for identifying cells expressing a target single chain antibody (scFv) directed against a target antigen from a collection of cells that includes cells that do not express the target scFv, comprising the step of combining the collection of cells with an anti-idiotype directed to an antibody specific for the target antigen and detecting interaction, if any, of the anti-idiotype with the cells, wherein the occurrence of an interaction identifies the cell as one which expresses the target scFv. This invention also provides a method for making a single chain antibody (scFv) directed against an antigen, wherein the selection of clones is made based upon interaction of those clones with an appropriate anti-idiotype, and heretofore inaccessible scFv so made. This invention provides the above methods or any combination thereof. Finally, this invention provides various uses of these methods. | 09-09-2010 |
20100216743 | THERAPY-ENHANCING GLUCAN - This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition. | 08-26-2010 |
20100210649 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS - The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries. | 08-19-2010 |
20100168118 | Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin - The present invention relates to a method for assessing the sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaminopterin and a method for selecting a patient for treatment of cancer with 10-propargyl-10-deazaminopterin, by determining the amount of a selected polypeptide expressed by the cancer and comparing the amount with the amount of the selected polypeptide expressed by a reference cancer, wherein the polypeptide includes a member of folate pathways within cells and may include at least one of reduced folate carrier-1 enzyme (RFC-1), dihydrofolate reductase (DHFR), folylpoly-gamma-glutamate synthetase (FPGS), thymidylate synthase (TS), γ-glutamyl hydrolase (GGH), and glycinamide ribonucleotide formyltransferase (GARFT). The present invention also relates to the use of 10-propargyl-10-deazaminopterin in the treatment of multiple myeloma. | 07-01-2010 |
20100156413 | CORRECTED NUCLEAR MAGNETIC RESONANCE IMAGING USING MAGNETIZATION TRANSFER - Techniques for corrected nuclear magnetic resonance (NMR) data include applying a presaturation radio frequency (RF) magnetic field different from a fat molecule resonance for a particular time to a target tissue; and applying a first measurement RF magnetic field within a first time after the particular time. Correction nuclear magnetic resonance (NMR) data from the target tissue is determined based on first NMR data received in response to applying the first measurement RF magnetic field. In some embodiments, a second measurement RF magnetic field is also applied in a second time different from both the particular time and the first time. Corrected NMR data is determined by subtracting the correction NMR data from second NMR data received in response to applying the second measurement RF magnetic field. Among other applications, these techniques allow distinguishing either fat or proteins in edemas, or both, from proteins in other tissues. | 06-24-2010 |
20100143245 | USES OF MONOCLONAL ANTIBODY 8H9 - The present invention discloses monoclonal antibody 8H9 which binds to the 4Ig domain isoform of the human B7-homolog 3, 4Ig-B7H3. The present invention provides a method of improving the prognosis or prolonging the survival of a subject bearing tumor cells, the method comprises administering to the subject a composition comprising an effective amount of an agent capable of binding to an antigen recognized by monoclonal antibody 8H9. | 06-10-2010 |
20100120777 | Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin - T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m | 05-13-2010 |
20100111986 | WT1 HLA Class II-Binding Peptides and Compositions and Methods Comprising Same - This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same. | 05-06-2010 |
20100093081 | METHODS AND COMPOSITIONS FOR PROMOTING SURVIVAL & PROLIFERATION OF ENDOTHELIAL CELLS & STIMULATING ANGIOGENESIS - The present invention relates to adenovirus E4ORF 1 gene and to endothelial cells engineered to express the E40RF 1 gene. The present invention also relates to uses of the E40RF 1 gene, and cells expressing the E40RF1 gene, and to compositions comprising the E4ORF 1 gene, or comprising cells expressing the E4ORF 1 gene. | 04-15-2010 |
20100068263 | Method and Compositions for Stimulation of an Immune Response to TRP2 using a Xenogeneic TRP2 Antigen - Tolerance of the immune system for endogenous TRP2 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed TRP2 antigen. For example, mouse TRP2, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against TRP2 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing TRP2, such as melanoma. | 03-18-2010 |
20100068262 | Method and Compositions for Stimulation of an Immune Response to PSMA using a Xenogeneic PSMA Antigen - Tolerance of the immune system for endogenous PSMA can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed PSMA antigen. For example, mouse PSMA, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against PSMA expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing PSMA, such as prostate cancer. | 03-18-2010 |
20100068216 | Method and Compositions for Stimulation of an Immune Response to gp100 using a Xenogeneic gp100 Antigen - Tolerance of the immune system for endogenous gp100 can be overcome and an immune response stimulated by administration of xenogeneic or xenoexpressed gp100 antigen. For example, mouse gp100, or antigenically-effective portions thereof, can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of xenogeneic antigens in accordance with the invention results in an effective immunity against gp100 expressed by the cancer in the treated individual, thus providing a therapeutic approach to the treatment of cancers expressing gp100, such as melanoma. | 03-18-2010 |
20100029748 | Metastasis Promoting Genes and Proteins - Two sets of genes and their encoded proteins, one set of 17 genes/proteins and one set of 18 genes/proteins that can be used in predicting the risk of cancer metastasis to the brain, and as a screening assay to identify the suitable treatments for brain metastases. Genes/proteins within the sets that are found to be differentially expressed relative to a control value are suitable targets for therapy. | 02-04-2010 |
20100015615 | Identification and Isolation of Adult Stem Cells and Related Methods of Use - Inhibitor of DNA Binding-1 (Id-1) is a marker protein found in stem cells, including adult stem cells, which can be used an indicator of the “stem-ness” of the cells. This allows Id1 expression to be used in a method for identifying cells as potential stem cells involving the step of screening the cells for expression of Id1; and a method for isolating cells as potential stem cells comprising the step of separating cells that express Id1 from cells that do not. Expression of GFAP can be used as a secondary screen to isolate rare B1 type adult neuronal stem cells. | 01-21-2010 |
20100008853 | ANTI GANGLIOSIDE GD3 ANTIBODIES AND USES THEREOF - The present invention is related to complementarity determining region (CDR)-grafted humanized R24 antibodies that bind to the GD3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine R24 antibody, and the humanized antibodies are useful in treating cancer (e.g. melanoma). | 01-14-2010 |
20100001838 | Automated Association of Patient Care Devices - Techniques for associating assets of a medical care facility include receiving a first data flow that indicates a first unique identifier for a first radio frequency identification (RFID) tag and receiving a second data flow that indicates a second unique identifier for a second RFID tag. Also received is database data that associates the first unique identifier with a first asset and associates the second unique identifier with a different second asset. It is determined whether a position of the first RFID tag is within operative distance of a position of the second RFID tag based on the first data flow and the second data flow and the associated first asset and second asset. If it is determined that the position of the first RFID tag is within operative distance of the position of the second RFID tag, then the first asset is automatically associated with the second asset. | 01-07-2010 |
20090298857 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 - Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain. | 12-03-2009 |
20090274728 | Mutant Viruses - An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses. | 11-05-2009 |
20090208921 | METHODS OF DETECTION OF CANCER USING PEPTIDE PROFILES - The disclosed methods address the identification and monitoring of cancer in a subject using serum peptide profiles. Such profiles allow the detection of the differential presence of certain serum peptide markers in comparison with controls. The profiles can be determined employing mass spectrometry. | 08-20-2009 |
20090023142 | Methods for Detecting Minimum Residual Disease - The present invention features methods and compositions for identifying markers of minimum residual disease (MRD), as well as markers of metastatic cells. The present invention further provides methods for detecting MRD and metastatic cell in a subject. | 01-22-2009 |
20080317752 | Inhibition of Tumorigenesis by Inhibition of a6b4 Integrin - Inhibitors of a6b4 integrin that target beta 4 are used as therapeutic agents to inhibit tumorigensis in individuals, including humans, of tumors that express a6b4 integrin. The therapeutic agent may be an antibody or a small molecule, for example a laminin-5 analog, which binds to a6b4 integrin and inhibits its normal function. The therapeutic agent may also be a chemical species that interferes with the production of beta 4, including for example an antisense or RNAi species. The therapeutic agent is administered to the tissue or patient in a therapeutically effective amount. The therapeutic agent may be used as a single agent or in combination with other therapies, especially those directed toward suppressing the activity of RPTKs known to cooperate with a6b4, including but not limited to ErbB2, EGF-R, Met, and Ron. | 12-25-2008 |
20080253965 | Small-Molecule Hsp90 Inhibitors - Hsp90 inhibitors are provided having the formula: | 10-16-2008 |
20080213258 | Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung - A signature for breast cancer tissue derived from a patient is established that is indicative of the virulence and risk of lung metastasis by determining the expression levels to define a sample signature, and comparing this sample signature to a reference signature. The reference signature defines a standard expression level for each gene and a significant change direction, i.e., either overexpressed or underexpressed. A sample signature that differs from the reference signature in the significant change direction for a predetermined number of the genes tested is indicative of a significant risk of lung metastasis. This determination is used to define appropriate treatment and monitoring options for the patient. Risk of metastasis to the lung can be reduced by treatment with a therapeutic combination that either (1) contains a first agent effective to inhibit epiregulin activity and a second agent effective to inhibit activity of a protein selected from the group consisting of MMP1, MMP2 and PTGS2, or (2) contains a therapeutic agent or combination of agents effective to inhibit activity MMP1, MMP2 and PTGS2. Agents that inhibit the CXCL1 pathway also can be used individually or in combination with these combinations. | 09-04-2008 |